Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease, 1st Edition
Author :
Fred Poordad
Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review ar ...view more
Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.
Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.
Author Information
By Fred Poordad, MD, University of Texas Health Science Center, San Antonio, Texas
https://www.us.elsevierhealth.com/hepatitis-c-direct-acting-antivirals-the-new-standard-of-care-an-issue-of-clinics-in-liver-disease-9781455711079.html6666Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Diseasehttps://www.us.elsevierhealth.com/media/catalog/product/9/7/9781455711079_7.jpg98.9998.99USDInStock/Medicine/Hepatology/Clinics/Clinics1434388725525504113841826925145120Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient. Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.00add-to-cart97814557110792011 and earlierProfessionalBy Fred Poordad, MD20111Book152w x 229h (6.00" x 9.00")Saunders0Sep 22, 2011IN STOCK - This may take up to 5 business days to shipBy <STRONG>Fred Poordad</STRONG>, MD, University of Texas Health Science Center, San Antonio, TexasClinicsClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
